Drug Combo Might Offer Hope for Some Brain Tumor Patients
Note: There is multimedia content on this page which requires the Flash viewer.
To see it, download and install the Flash plugin here: Macromedia Flash Player
Dr. James Vredenburgh, Duke neuro-oncologist and lead investigator, offers a few comments on a new Duke study that shows a combination of bevacizumab -- commonly known as Avastin -- and a standard chemotherapy agent, may increase the amount of time GBM patients can survive without tumor growth, and may significantly increase their overall survival. In part, the combination of drugs chokes off a tumor's blood supply.